Evidence map›Paper›PMID 30784352›Full record

ReviewNucleus (Austin, Tex.)2019

Novel contribution of epigenetic changes to nuclear dynamics.

Marcel Dreger, Elena Madrazo, Adam Hurlstone, Javier Redondo-Muñoz

Abstract readReview
In one paragraph

Review in Nucleus (Austin, Tex.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marcel Dregera Faculty of Biology, Medicine and Health, Division of Cancer Studies , School of Medical Sciences, The University of Manchester , Manchester , UK.ORCID 0000-0002-2852-0345
Elena Madrazob Department of Immunology Ophthalmology and ENT, Hospital 12 de Octubre Health Research Institute (imas12) , Complutense University, School of Medicine , Madrid , Spain.ORCID 0000-0002-0404-572X
Adam Hurlstonea Faculty of Biology, Medicine and Health, Division of Cancer Studies , School of Medical Sciences, The University of Manchester , Manchester , UK.ORCID 0000-0001-5260-9457
Javier Redondo-Muñozb Department of Immunology Ophthalmology and ENT, Hospital 12 de Octubre Health Research Institute (imas12) , Complutense University, School of Medicine , Madrid , Spain.ORCID 0000-0003-0607-2171

Funding

Wellcome Trust
6 · The paper itself

Abstract

Migrating cells have to cross many physical barriers and confined in 3D environments. The surrounding environment promotes mechano- and biological signals that orchestrate cellular changes, such as cytoskeletal and adhesion rearrangements and proteolytic digestion. Recent studies provide new insights into how the nucleus must alter its shape, localization and mechanical properties in order to promote nuclear deformability, chromatin compaction and gene reprogramming. It is known that the chromatin structure contributes directly to genomic and non-genomic functions, such as gene transcription and the physical properties of the nucleus. Here, we appraise paradigms and novel insights regarding the functional role of chromatin during nuclear deformation. In so doing, we review how constraint and mechanical conditions influence the structure, localization and chromatin decompaction. Finally, we highlight the emerging roles of mechanogenomics and the molecular basis of nucleoskeletal components, which open unexplored territory to understand how cells regulate their chromatin and modify the nucleus.

Indexed as

Cell NucleusEpigenesis, GeneticHumanscell migrationchromatinEpigeneticsmechanogenomicsnuclear mechanics

Identifiers

PMID30784352
PMCPMC6527383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.